Differences in Parkinson’s Disease populations: teaching hospitals versus other settings and implications for clinical trials
Gros P, Marras C, Wang X, Chiu M, Farkouh ME, Emdin A, Bronskill SE. Mov Disord. 2025; May 29 [Epub ahead of print].
Publications
Net health system costs of Parkinson disease: a propensity score-matched health administrative data cohort study in Ontario, Canada
Maclagan LC, Emdin A, Fu L, Guan J, de Oliveira C, Marras C, Bronskill SE. Neurol Clin Pract. 2025; 15(1):e200371. Epub 2024 Oct 8.
Trends in health service use among persons with Parkinson’s disease by rurality: a population-based repeated cross-sectional study
Maclagan LC, Marras C, Sewell IJ, Wu CF, Butt DA, Tu K, Bronskill SE. PLoS One. 2023; 18(5):e0285585. Epub 2023 May 19.
Trends in health service use among persons with Parkinson’s disease by rurality: a population-based repeated cross-sectional study
Maclagan LC, Marras C, Sewell IJ, Wu CF, Butt DA, Tu K, Bronskill SE. PLoS One. 2023; May 19 [Epub ahead of print].
Trends in health service use for Canadian adults with dementia and Parkinson disease during the first wave of the COVID-19 pandemic
Bronskill SE, Maclagan LC, Maxwell CJ, Iaboni A, Jaakkimainen RL, Marras C, Wang X, Guan J, Harris DA, Emdin A, Jones A, Sourial N, Godard-Sebillotte C, Vedel I, Austin PC, Swartz RH. JAMA Health Forum. 2022; 3(1):e214599. Epub 2022 Jan 21.
Exposure to phosphoglycerate kinase 1 activators and incidence of Parkinson’s disease
Gros P, Wang X, Guan J, Lang AE, Austin PC, Welk B, Visanji NP, Marras C. Mov Disord. 2021; 36(10):2419-25. Epub 2021 Jul 9.
Survival and healthcare use after deep brain stimulation for Parkinson’s Disease
Crispo JAG, Lam M, Le B, Shariff SZ, Ansell DR, Squarzolo M, Ouellette D, Thibault DP, Marras C, Willis AW, Seitz D. Can J Neurol Sci. 2021; 48(3):372-82. Epub 2020 Aug 28.
Beta agonists and progression of Parkinson’s disease in older adults a retrospective cohort study
Marras C, Pequeno P, Austin PC, Gershon AS, Iqbal J, Rochon PA, Lang AE. Mov Disord. 2020; 35(7):1275-7. Epub 2020 May 15.
Identifying drugs with disease‐modifying potential in Parkinson’s disease using artificial intelligence and pharmacoepidemiology
Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. Pharmacoepidemiol Drug Saf. 2020; 29(8):864-72. Epub 2020 May 14.
Disparities in deep brain stimulation use for Parkinson’s Disease in Ontario Canada
Crispo JAG, Lam M, Le B, Richard L, Shariff SZ, Ansell DR, Squarzolo M, Marras C, Willis AW, Seitz D. Can J Neurol Sci. 2020; 47(5):642-55. Epub 2020 Apr 24.